Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Fermer
Nikkei 225
39 810,88
0,00%
  2. Aide
  2. Aide
Investir à 0€ de frais de courtage sur plus de 45 000 produits
Découvrir Boursomarkets
Nikkei 225
39 810,88
0,00%
Indices
 
Chiffres-clés
 
+ fortes hausses et baisses SBF 120

Britain to provide anti-viral drug remdesivir to some COVID-19 patients
information fournie par Reuters 26/05/2020 à 12:15

LONDON, 26 mai (Reuters) - Britain will provide anti-viral drug remdesivir to certain COVID-19 patients that it is most likely to benefit as part of a collaboration with manufacturer Gilead Sciences GILD.O , the health ministry said on Tuesday.

The department of health said that early data from clinical trials around the world, including the UK, showed that the drug could shorten the recovery time of COVID-19 patients by 4 days. It did not say how many patients would be treated under the arrangement.

(Reporting by Alistair Smout and Kate Holton; editing by Guy Faulconbridge)

Valeurs associées

GILEAD SCIENCES
111,0000 USD NASDAQ -0,46%
© 2025 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

Cette liste ne contient aucune valeur.

Pages les plus populaires

L'offre BoursoBank